ArticleFrontiers in immunology2025
Nasal delivery of killed
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Investigation of the Immunomodulatory Effects of Combined Prebiotic, Probiotic, and Postbiotic Mixtures in Chicken Ileal Explant Cultures.Animals : an open access journal from MDPI · 2026Article
- Advances in Feline Panleukopenia Virus Vaccines: Immunological Mechanisms, Current Challenges, and Future Perspectives.Viruses · 2026Review
- Heat-inactivated Bacillus spores attenuate poly I:C-induced lung inflammation and microbiome alterations through modulation of host immune responses.Scientific reports · 2026Article
- Construction of the Multi-Epitope HFMD Vaccine Based on an Attenuated CVB3 Vector and Evaluation of Immunological Responses in Mice.Vaccines · 2026Article
- The Airway Microbiome as a Modulator of Influenza Virus Infection: Mechanistic Insights and Translational Perspectives-Review.Pathogens (Basel, Switzerland) · 2026Review
- Mucosal Vaccination Against SARS-CoV-2 Using Human ProbioticVaccines · 2025Article
- Memory T Cells in Respiratory Virus Infections: Protective Potential and Persistent Vulnerabilities.Medical sciences (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Spores of the bacterium Methods: Results: We found that mice pre-treated with spores developed resistance to all three pathogens and, in each case, exhibited a significant improvement in both survival rate and disease severity. Intranasal spore dosing expanded alveolar macrophages and induced recruitment of leukocyte populations, providing a cellular mechanism for the protection. Most importantly, virus-induced inflammatory leukocyte infiltration was attenuated in spore-treated lungs, which may alleviate the associated collateral tissue damage that leads to the development of severe conditions. Remarkably, spores were able to promote the induction of tissue-resident memory T cells, and, when administered following an intramuscular prime with SARS-CoV-2 spike protein, increased the levels of anti-spike IgA and IgG in the lung and serum. Conclusions: Taken together, our results show that
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.